In Vitro and In Vivo Test of Boron Delivery Agent for BNCT

Sista Dyah Wijaya (Pharmaceutical Science and Technology, School of Pharmacy, Bandung Institute of Technology)
Bagaswoto Poedjomartono (Department of Radiology, Radio Nuclear Services, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada)
Yohannes Sardjono (Pusat Sains Dan Teknologi Akselerator Badan Tenaga Nuklir Nasional (PSTA BATAN) / Center of Science and Technology of Accelerator National Nuclear Energy Agency)

Indonesian Journal of Physics and Nuclear Applications
Vol 4 No 2 (2019)

BNCT is an alternate therapy for treating cancer. The principle of BNCT involves a neutron boron uptake and a fission reaction that produce alpha particles and Li ions with a high level of linear energy transfer in the tissue. It is effective in killing tumor cells. To administer boron in the tumor cells, a boron delivery agent is needed. Thus far, there are a variety of boron delivery agents that have been developed. To date, just two main boron-based drugs, BPA and BSH, have been used for clinical studies. Many other boron delivery agents have been evaluated in vivo and in vitro but have not been evaluated clinically. Therefore, the other boron delivery agents have not been used in BNCT clinical studies.